TY - JOUR
T1 - Erratum
T2 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma (Journal for ImmunoTherapy of Cancer (2020) 8 (e001235) DOI: 10.1136/jitc-2020-001235)
AU - Neelapu, S. S.
AU - Adkins, S.
AU - Ansell, S. M.
N1 - Publisher Copyright:
© Author(s) 2021.
PY - 2021/1/18
Y1 - 2021/1/18
N2 - Neelapu SS, Adkins S, Ansell SM, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer 2020;8:e001235. doi: 10.1136/jitc-2020-001235 In the Panel recommendations for Burkitt's lymphoma, the statement 'Options include rituximab+Lymphome Malins de Burkitt (R-LMB), rituximab+cyclophosphamide+ doxorubicin+methotrexate / ifosfamide+etoposide+cytarabine (R-CODOXM/ IVAC), DA-R- EPOCH, rituximab+ German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Protocol (R-GMALL), and rituximab+cyclophosphamide+- doxorubicin+dexamethasone+pegfilgrastim alternating with rituximab+methotrexate+ cytarabine (R-HyperCAD)' has been corrected as below to add vincristine, omit pegfilgrastim and correct the acronym from 'R-HyperCAD' to 'R-HyperCVAD': 'Options include rituximab+Lymphome Malins de Burkitt (R-LMB), rituximab+cyclophosphamide+ doxorubicin+methotrexate / ifosfamide +etoposide+cytarabine (R-CODOXM/ IVAC), DA-R- EPOCH, rituximab+German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Protocol (R-GMALL), and rituximab+cyclophosphamide+ vincristine+doxorubicin+dexamethasone alternating with rituximab+methotrexate+ cytarabine (R-HyperCVAD).
AB - Neelapu SS, Adkins S, Ansell SM, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer 2020;8:e001235. doi: 10.1136/jitc-2020-001235 In the Panel recommendations for Burkitt's lymphoma, the statement 'Options include rituximab+Lymphome Malins de Burkitt (R-LMB), rituximab+cyclophosphamide+ doxorubicin+methotrexate / ifosfamide+etoposide+cytarabine (R-CODOXM/ IVAC), DA-R- EPOCH, rituximab+ German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Protocol (R-GMALL), and rituximab+cyclophosphamide+- doxorubicin+dexamethasone+pegfilgrastim alternating with rituximab+methotrexate+ cytarabine (R-HyperCAD)' has been corrected as below to add vincristine, omit pegfilgrastim and correct the acronym from 'R-HyperCAD' to 'R-HyperCVAD': 'Options include rituximab+Lymphome Malins de Burkitt (R-LMB), rituximab+cyclophosphamide+ doxorubicin+methotrexate / ifosfamide +etoposide+cytarabine (R-CODOXM/ IVAC), DA-R- EPOCH, rituximab+German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Protocol (R-GMALL), and rituximab+cyclophosphamide+ vincristine+doxorubicin+dexamethasone alternating with rituximab+methotrexate+ cytarabine (R-HyperCVAD).
UR - http://www.scopus.com/inward/record.url?scp=85100214417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100214417&partnerID=8YFLogxK
U2 - 10.1136/jitc-2020-001235corr1
DO - 10.1136/jitc-2020-001235corr1
M3 - Comment/debate
C2 - 33462139
AN - SCOPUS:85100214417
SN - 2051-1426
VL - 9
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 1
M1 - 001235
ER -